10-Q · May 6, 2026
Ardent Health, Inc. reported robust Q1 2026 performance with a revenue of $1.60 billion, marking a 7.0% increase from $1.50 billion in Q1 2025, while EPS improved to $0.28 from $0.29 year-over-year. Management…
Earnings analysis · 10-Q
ARDT earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Ardent Health's Q2 performance weakened materially versus the prior year: revenue declined 1.4% to $1.622 billion, net income attributable to the company fell to $16.9 million from $73.0 million, and diluted EPS…
Read full summary
Ardent Health's Q2 performance weakened materially versus the prior year: revenue declined 1.4% to $1.622 billion, net income attributable to the company fell to $16.9 million from $73.0 million, and diluted EPS declined to $0.12 from $0.52. Volume trends were more resilient, with adjusted admissions up 2.5%, but lower revenue per adjusted admission and higher professional fees pressured profitability. Liquidity and operating cash flow improved, with $992.5 million of available liquidity and $136.5 million of first-half operating cash flow, but Medicaid-policy exposure, labor costs, and variable-rate debt remain significant risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.12
What stood out
-
Volume growth partially offset revenue decline
Q2 revenue was $1.622 billion, down $23.0 million, or 1.4%, year over year, and approximately 0.8% above Q1 2026 revenue of $1.6 billion. Adjusted admissions increased 2.5% year over year to 89,326.
-
Earnings and EPS declined sharply
Net income attributable to Ardent Health fell to $16.9 million from $73.0 million in Q2 2025, while diluted EPS was $0.12 versus $0.52 a year earlier and $0.28 in Q1 2026.
-
Productivity gains offset by physician costs
Operating cost pressure increased: professional fees rose to $327.8 million from $297.0 million, or 20.2% of revenue versus 18.1%, primarily due to higher hospital-based physician costs.
-
First-half revenue and volume remained positive
Six-month revenue increased 2.6% to $3.224 billion, supported by 2.3% growth in adjusted admissions and a 0.6% increase in net patient service revenue per adjusted admission to $18,111.
-
Cash generation improved despite lower earnings
Operating cash flow for the six months rose to $136.5 million from $92.7 million, driven primarily by a $102.9 million positive working-capital contribution. Capital expenditures were $66.8 million, implying approximately $69.7 million of six-month operating cash flow less capex.
-
Balance-sheet liquidity remained solid
Liquidity was $992.5 million at June 30, 2026, consisting of $724.5 million of cash and cash equivalents and $268.0 million of available ABL capacity; net leverage was 0.8x.
What to watch
-
Medicaid and reimbursement pressure
Medicaid supplemental-payment revenue declined by $57.8 million year over year in Q2, and management states that the OBBBA may reduce Medicaid funding. The legislation could also result in Medicare reimbursement cuts of up to 4% under sequestration if Congress does not act.
-
Labor and physician-cost inflation
Professional fees increased to $327.8 million, or 20.2% of revenue, from $297.0 million, or 18.1%, as hospital-based provider costs rose. Management also cites physician shortages, outsourced-specialist insolvencies, and inflationary wage pressure as potential threats to admissions and margins.
-
Debt and long-term lease obligations
The company had $761.1 million of outstanding variable-rate debt, with a 1 percentage-point interest-rate change estimated to affect annual interest expense by $3.8 million. Contractual obligations totaled $4.545 billion, including $2.822 billion of operating lease obligations.
-
Regulatory transition remains unresolved
The filing states there were no material changes to previously disclosed risk factors. Nevertheless, the OBBBA's Medicaid eligibility and funding changes must be implemented by December 31, 2026, while no Rural Health Transformation Program funds had been received during the six months ended June 30, 2026.
Management's outlook
The 10-Q does not provide new quantitative revenue, EBITDA, net income, or EPS guidance. Prior outlook changes were disclosed in the August 4, 2026 earnings release rather than this filing.
Earlier filings 4
10-K · March 16, 2026
Ardent emphasizes a JV-driven, consumer-centric hospital and ambulatory platform built around scale, technology and value-based care — operating 30 acute care hospitals, more than 280 sites of care, and over 2,000…
10-Q · May 7, 2025
Ardent reported Q1 2025 revenue of $1,497,234,000, up $58,188,000 (4.0%) year-over-year from $1,439,046,000, and diluted EPS of $0.29 versus $0.21 in Q1 2024. Income before income taxes rose to $74,198,000 helped by a…
10-K · February 27, 2025
Ardent presents a scaled, regionally concentrated hospital and ambulatory platform with 30 acute care hospitals, ~280 sites of care and over 1,800 providers as of December 31, 2024, and says it served approximately 1.2…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.